Nebenwirkungen · Comirnaty
Comirnaty KP.2 30 micrograms/dose dispersion for injection Comirnaty KP.2 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty KP.2 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 79
HOS-149018 · Präparat HOS-099980
Participants 12 years of age and older – after a booster dose of Comirnaty Original/Omicron BA.4-5 (fourth dose) In a subset from Study 5 (Phase 2/3), 107 participants 12 to 17 years of age, 313 participants 18 to 55 years of age and 306 participants 56 years of age and older who had completed 3 doses of Comirnaty, received a booster (fourth dose) of Comirnaty Original/Omicron BA.4-5 (15/15 mcg) 5.4 to 16.9 months after receiving Dose 3. Participants who received a booster (fourth dose) of Comirnaty Original/Omicron BA.4-5 had a median follow-up time of at least 1.5 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 7e4f1bfba17cb0f6d83c97d499a22be96d0aedc2f3e4e749f3e8a6a2bc9348e7 · Zeichen 11757–12337 im Abschnitt